GLENMARK PHARMACEUTICALS
Long
Aggiornato

Curve pattern in Glenmark pharma

Dee the result of last similar formation highlighted in the chart.
Trade attivo
Glenmark Pharma reported better than expected EBITDA and EBITDA margin.

· Q1 net profit Rs254cr (up 132% YoY) – expectation Rs144cr,

· Ebitda Rs478cr (up 40% YoY) – expectation Rs372cr,

· EBITDA margin 20.4% vs 14.5% (YoY) – expectation 14.8%

· Income Rs Rs2345cr (up 1% YoY)- expectation Rs2515cr

Declinazione di responsabilità